PhorMed

PhorMed

Utilizing gene therapy to target cancer and mutated cells
Beverly Hills, 
CA
Investment type:
Equity
(Common Stock)
Target raise:
$10,000
 - $1,070,000
Minimum investment:​
$250
End date:
Jul 10, 2020
ended
Share
Share on facebook
Share on twitter
Share on linkedin
Share on email
PhorMed is a biopharmaceutical company leading the charge in the field of genomic medicine. We utilize gene therapy to target cancer and mutated cells, allowing the body to begin healing itself, and give new hope to patients suffering from diseases like AML, Hodgkin’s Lymphoma and Parkinson’s, among others.
Our Story

The drug is administered through intravenous infusion, with patients treated in 3-5 cycles. Each cycle is approximately one month in duration, with five treatments per week, followed by a two week rest period. Treatment recipients are not required to remain in the hospital thanks to the limited side effects and unobtrusive nature of the drug.
Our Ambition

Phase II Clinical Trials are targeted for completion in the next 2.5 years. During the same period, the goal is to complete multiple licensing deals with pharmaceutical and/or biotech companies. These major steps will precipitate expansion of our pipeline and the potential placement of multiple products in the marketplace.  We anticipate that in the next 3-4 years our company will be able to take advantage of the growing market and help fulfill unmet medical needs.